Hypoglycaemia in diabetes

• Autores: Simon Heller, Elaine Chow
• Localización: Medicine, ISSN-e 1357-3039, Vol. 42, Nº. 12, 2014, págs. 727-731
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Hypoglycaemia is a feared and common unwanted effect of diabetes treated with insulin or sulfonylureas, and is the main reason why insulin-treated individuals often fail to achieve the levels of glycaemic control necessary to prevent diabetic complications. Normal brain function depends upon a continuous supply of glucose. If blood glucose falls below normal, interruption of this supply leads to cerebral dysfunction and, if it is not corrected, confusion and coma. Hypoglycaemia results chiefly from the inability of current glucose-lowering therapies to reproduce the physiology of the pancreatic β-cell, leading to inappropriately high insulin concentrations between meals and at night. Early after diagnosis, patients are partly protected by ‘physiological’ defences to hypoglycaemia that ensure release of adrenaline and glucagon as glucose falls below normal, and resist the glucose-lowering effect of insulin. In addition, activation of the sympatho-adrenal system provokes symptoms that patients learn to recognize and treat by eating or drinking. With increasing duration of diabetes, and following episodes of hypoglycaemia, these defences become impaired and patients are increasingly at risk of severe episodes, particularly if they develop ‘hypoglycaemia unawareness’. Hypoglycaemia may be reduced through patient education and individualized glycaemic targets. Newer insulin delivery and glucose-sensing technologies offer promise for those in whom this is a recurrent problem.